BioNTech (BNTX) Could Be 81% Undervalued After New Vaccine Patent Lawsuits
Arbutus Biopharma and Genevant Sciences have launched new patent lawsuits targeting lipid nanoparticle technology used in Pfizer BioNTech (NasdaqGS:BNTX) COVID-19 vaccines. The actions seek monetary damages and potential injunctions across Canada and multiple European countries.
See our latest analysis for BioNTech.
For investors, the latest lawsuits arrive after a weaker period for BioNTech’s stock, with the share price at US$92.95 and short term momentum softening following a 90 day share price return that declined 10.15%, while the 1 year total shareholder return is down 15.54%.
If you are assessing how this legal risk fits into a broader biotech watchlist, it can be useful to compare BioNTech with other companies using a healthcare focused AI stocks screener such as 41 healthcare AI stocks
BioNTech’s share price has already absorbed a weak year and fresh legal headlines. The decision now is whether that mix of legal overhang and vaccine exposure is already reflected in the valuation or whether it is worth waiting for a cheaper entry.
Most Popular Narrative: 81.4% Undervalued
The leading narrative for BioNTech values the stock at $499.94 per share compared with the last close of $92.95, which is a large gap to understand.
"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles.
Sahin with his strength of pattern recognition and complexity reduction would certainly have started with an IT company, like many others. It is a stroke of luck that he has decided to fight against the Geissesl of humanity, because it is clear that medicine with AI, robotics and the breakdown of human metabolism into algorithms is facing a fundamental change.
According to Hansimglueck, this fair value leans heavily on ambitious revenue growth, higher profit margins, and a premium future earnings multiple. Curious which specific assumptions drive that $499.94 figure and the 81.4% gap to the current BioNTech share price.
Result: Fair Value of $499.94 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this bullish BioNTech narrative still faces clear risks, including ongoing patent litigation around vaccine technology and execution challenges across its broad clinical trial pipeline.
Find out about the key risks to this BioNTech narrative.
Another View On BioNTech’s Valuation
While the community narrative points to a fair value of $499.94 per BioNTech share, the current P/S ratio of 7.3x paints a different picture. It is higher than both the fair ratio of 5.3x and the peer average of 6.1x, which hints at valuation risk rather than a clear bargain. This raises the question of whether the market is paying a premium for future potential that may take time to materialize.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Looking For More Investment Ideas Beyond BioNTech?
If you want more context around BioNTech, compare it with other opportunities using focused stock screens that highlight quality, value, and resilience.
- Spot potential value opportunities early by scanning companies highlighted through the 48 high quality undervalued stocks.
- Prioritise resilience and steadier profiles by reviewing companies featured in the 85 resilient stocks with low risk scores.
- Hunt for lesser known opportunities with strong fundamentals using the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com